Fig. 2

Distribution of cryocrit levels (a), rheumatoid factor activity (b) and complement component C4 levels (c) in 22 hepatitis C virus-positive patients with cryoglobulinaemia treated with direct-acting antiviral agents at baseline, at week 4, at the end of treatment (EoT) and 12 weeks after treatment. SVR12 Sustained virological response 12 weeks after therapy completion